NEXALIN TECHNOLOGY INC

Company Overview

Nexalin Technology Inc. is a Houston‑based medical device company developing non‑invasive bioelectronic neurostimulation systems (Gen‑1, Gen‑2 clinical unit and Gen‑3 HALO headset) aimed at treating anxiety, insomnia and depression without drugs. Commercial activities today are modest and lumpy — near‑term revenue is largely from legacy Gen‑1 placements, recurring single‑use electrode sales (RFID tracked), licensing/treatment fees and occasional equipment shipments to international partners, while full U.S. commercialization depends on planned pivotal trials, FDA reviews and wider roll‑out of a telehealth “virtual clinic” model. Operations are very lean (six full‑time employees, outsourced manufacturing and a Hong Kong JV for China), and the business is highly dependent on regulatory outcomes (FDA reclassification issues), clinical results, JV execution in China and periodic capital raises. Liquidity is constrained (cash under $1M at year‑end 2024 and ~ $431k mid‑2025, with accumulated deficits >$80M), so execution and financing risk are material near‑term factors.

Executive Compensation Practices

Given the company’s cash constraints and stage, executive pay is materially equity‑heavy: filings show a sharp increase in stock‑based compensation ($~2.25M incremental in 2024 and ~$260k in Q2 2025), indicating reliance on options/restricted stock to preserve cash. Performance metrics that are likely to drive incentive design are regulatory and clinical milestones (FDA pre‑submissions, trial starts and outcomes), recurring electrode/licensing revenue growth, international approvals/commercialization (notably China via the JV), and successful fundraising or margin expansion. As a small medical‑device developer, compensation mix is likely to follow industry norms — modest base salaries supplemented by milestone‑linked long‑term incentives and time‑based equity to retain key technical and regulatory talent. The board will also need to balance dilution risk versus retention needs given frequent financing and the company’s stated going‑concern uncertainty.

Insider Trading Considerations

Insider activity can be particularly informative here because the team is small and insiders may hold concentrated positions; equity financing events and option grants have been frequent, so insider holdings and Form 4 filings often reflect both compensation and liquidity actions. Material nonpublic events that could drive insider trades include FDA interactions (Q‑subs/PMA timelines), clinical trial enrollment/results, JV funding or commercial contract milestones (China shipments), and capital raises — all of which are likely to be treated as blackout triggers for insiders and should be watched for pre‑planned (10b5‑1) trading. Regulatory sensitivity (Class III pathway for depression) and the equity‑accounted JV create additional sources of material information; investors should monitor timing of Form 4s relative to 8‑Ks/press releases to distinguish routine selling for liquidity from potentially informative opportunistic trades.